Fadugba Olajumoke

Fadugba Olajumoke, a woman-owned small business sole proprietorship based in Drexel Hill, Pennsylvania, provides specialized medical expert services—case review, expert analysis of vaccine injury claims, and expert witness testimony—to federal agencies as a prime contractor under total small business set-asides and full-and-open BPA calls. The vendor operates under NAICS 621111 (Offices of Physicians except Mental Health Specialists) and PSC code for expert witness support services, with all work performed at the Pennsylvania headquarters.

Customer concentration is extreme and singular: 47 of 50 awards (94% by count, 100% of potential value) flow from the Department of Health and Human Services Health Resources and Services Administration (HRSA) for the Vaccine Injury Compensation Program (VICP) and the related Countermeasures Injury Compensation Program (CICP). Three awards valued at $29 thousand total come from the Department of Justice Civil Division for expert witness services. HRSA is the operative customer across both rankings; the DOJ work represents residual volume at negligible dollar scale.

Fadugba Olajumoke holds two parent BPAs with HRSA. The primary vehicle is a $7.5 million single-award BPA (75R60224A00008) awarded July 19, 2024, running through July 18, 2029, which has generated 17 task orders carrying $267 thousand in combined potential value. A secondary $249,999 multiple-award BPA (75R60219A00103) for medical expert panel support has generated 28 task orders with $81 thousand combined potential value. Representative recent work includes a $37,500 BPA call awarded September 10, 2026, for VICP medical case review services; a $24,375 Competitive 8(a) set-aside BPA call from July 7, 2026; and a $16,125 time-and-materials purchase order from DOJ's Civil Division dated March 12, 2024, for expert witness services. Individual task orders under the HRSA BPAs typically carry firm-fixed-price ceilings ranging from $600 to $24,375, with the bulk designated as total small business set-asides and a smaller set issued full-and-open or without set-aside designation.

Activity has been episodic: 7 awards in 2022, 2 in 2023, 12 in 2024, 8 in 2025, and 5 in 2026 through September. Six awards with ultimate completion dates in the next twenty-four months carry combined potential value of $142 thousand, representing recompete exposure concentrated almost entirely on the HRSA VICP account. Combined obligated dollars across all 50 awards total $377 thousand against $8.1 million combined potential value (5% obligation rate), a pattern consistent with small-value, task-order-based service contracting. The vendor operates as a 100% prime contractor with no subcontract footprint and no reported federal contract vehicle holdings beyond the two HRSA BPAs described above.